New hope for drug-resistant lung cancer: combo therapy enters trial

NCT ID NCT07548060

Recruiting now Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs (Sacituzumab Tirumotecan and Furmonertinib) in 25 people with advanced non-squamous non-small cell lung cancer that has an EGFR gene mutation and has stopped responding to standard treatments. The goal is to see if the combo can shrink tumors or slow disease progression. Participants must have stage IIIB/IV cancer and have already tried EGFR-targeted therapy and platinum chemotherapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR GENE MUTATION NSCLC STAGE IV

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Tianjin Medical University Cancer Institute and Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300060, China

Contact Email: •••••@•••••